{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076617","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.268996+00:00","generated_at":"2026-05-15T23:45:06.589676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026","bullets":["Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).","Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.","Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.","Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.","Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076617","json":"https://secwatch.observer/filing/0001193125-26-076617.json","markdown":"https://secwatch.observer/filing/0001193125-26-076617.md","text":"https://secwatch.observer/filing/0001193125-26-076617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/0001193125-26-076617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/rlay-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:45:06.589676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}